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Background: England’s National Institute for Health and Care Excellence (NICE) and the US’ Institute for Clini-
cal and Economic Review (ICER) both conduct cost-effectiveness evaluations for new cancer drugs to help
payers make drug coverage decisions. However, NICE and ICER assessments have been noted to reach differ-
ent conclusions. We aim to better understand the degree to which their recommendations diverge and what
drives these apparent differences.
Methods: We compared the methods and results of publicly available cost-effectiveness evaluations per-
formed by ICER and NICE of similarly assessed cancer drugs. Assessments were compared based on incre-
mental cost-effectiveness ratio, comparator treatment, price, recommendation, and the design of the
economic evaluation.
Findings: Among 11 commonly assessed cancer drugs, ICER and NICE were in concordance for 7 evaluations
and in discordance on the cost-effectiveness and coverage decisions for 4 drugs. Most new cancer drugs
were not cost-effective in either the US (7/11) or England (7/11). Furthermore, NICE’s capacity to negotiate
price discounts and access schemes result in much lower cost per QALY valuations and more favourable rec-
ommendations than those of ICER for similarly assessed cancer drugs.
Interpretations: NICE and ICER employ similar health technology assessment (HTA) methodologies and were
aligned with most recommendations, finding that many new and expensive cancer drugs are cost ineffective.
Growing use of ICER assessments will continue to send stronger price signals to manufacturers that cancer
drugs with low value for money will be viewed less favourably by private insurers. NICE provides an impor-
tant reminder of how much lower other countries pay for drugs when comparative effectiveness and value-
based pricing are integrated into public drug coverage decisions.
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New therapeutics for cancer such as immune checkpoint inhibi-
tors and chimeric antigen receptor t-cell therapy (CAR-T), have
become available for treatment of advanced or metastatic tumors.
Many of these drugs have been priced very highly, raising important
debates about the degree to which they provide value [13]. When
comparing the value gained from new cancer drugs, the United States
is an outlier behind several high-income countries including Aus-
tralia, Canada and the United Kingdom on health gains per dollar
spent [4]. In several countries, cancer drugs are regularly appraised
by national health technology assessment (HTA) agencies to deter-
mine whether they represent a cost-effective use of public resources.In England, the National Institute for Health and Care Excellence
(NICE) appraises the clinical and cost-effectiveness of newly
approved therapies and issues recommendations for public coverage
in the National Health Service (NHS). In contrast, the US does not
have a national HTA agency largely for political and ideological rea-
sons that the government should not be involved in drug coverage
decisions. The Institute for Clinical and Economic Review (ICER) is an
independent, non-governmental research organization that is work-
ing to fill the HTA void in the US. ICER does not have a formal role for
evaluation or reimbursement. Rather, they conduct an analysis for
value-based pricing and budget impact which are being increasingly
used by private payers to inform price negotiations with pharmaceu-
tical companies. ICER’s assessments appear to be gaining traction
with a 2016 survey of US private payers finding that 59% of respond-
ents had used ICER reports in formulary decisions [5].
While NICE and ICER represent two of the largest and most conse-
quential HTA agencies, we know very little about how their
Fig. 1. Flowchart of cancer drugs evaluated for cost-effectiveness included in our
study. Abbreviations: The Institute for Clinical and Economic Review; ICER, the
National Institute for Health and Care Excellence, NICE.
Research in Context
Evidence before this study
The US does not have a formal HTA agency for evaluating the
clinical and cost-effectiveness of new drugs, therefore private
insurers have increasingly begun to rely on the Institute for
Clinical and Economic review (ICER) to make drug coverage
decisions in medicinal formularies. Whereas in England, the
National Institute for Health and Care Excellence (NICE) makes
national coverage decisions for the publicly funded National
Health Service. To our knowledge, no study has evaluated the
difference in cost-effectiveness valuations of cancer drugs
between these two agencies.
Added value of this study
We searched ICER and NICE appraisals for all similarly assessed
cancer drugs until November 2019. As they use similar data
and methods for determining cost-effectiveness, they come out
with remarkably similar results. But there are important ways
in which they diverge, largely due to contextual differences
between the US and English health systems, and because of
NICE’s capacity to engage in negotiating price discounts and
access schemes to drugs with uncertain therapeutic benefit or
economic value.
Implications of all the available evidence
Most new cancer drugs evaluated by HTA agencies in the US and
England are not cost-effective. Furthermore, discordance
between the two agencies regarding the cost-effectiveness of
newer cancer therapeutics is driven by the higher cost of health-
care and pharmaceuticals in the US inputted into economic
modeling.
2 A. Cherla et al. / EClinicalMedicine 2930 (2020) 100625methodologies compare or the degree to which they reach similar
conclusions. Studies by Chabot and Rocchi in 2014 [6], and Pinto and
colleagues in 2020 compared English and Canadian HTA for oncology
drugs [7] and both studies found variation in recommendations due
to differences in available policy tools to address issues of clinical
uncertainty and unfavorable cost-effectiveness.
We compared the methods and results of cost-effectiveness eval-
uations performed by ICER and NICE of similarly assessed cancer
drugs. We focused on cancer drugs because a host of them have
recently come on the market, many are purported to be quite clini-
cally useful, and most of them have very high price tags. We further
examined where these two agencies have concordance or discor-




Both ICER and NICE publish publicly available assessment
reports on the clinical and cost-effectiveness of new drugs. Every
assessment of a cancer drug evaluated by ICER was included in
the study. [8] As of November 2019, ICER has evaluated six cancer
indications (categorized under five ‘topics’) including; b-cell acute
lymphoblastic leukemia and b-cell lymphoma (included under the
topic chimeric antigen receptor T-cell therapies), multiple mye-
loma, non-small cell lung cancer, ovarian cancer and prostate
cancer. In total, 19 cancer drugs were appraised across the five
topics, 17 were evaluated with definitive estimates for cost-effec-
tiveness measured in cost per quality adjusted life year (QALY)from January 2016 through October 2018. The assessments of
abiraterone acetate for prostate cancer and daratumumab for
multiple myeloma did not include definitive estimates for cost-
effectiveness and were excluded from the analysis.
The 17 drugs with available estimates for cost-effectiveness were
similarly compared with publicly available technology appraisals
from NICE. Six drugs were excluded; three technology appraisals for
drugs were in development and three had estimates for cost-effec-
tiveness which were inconclusive or not estimable. Reports from
NICE often included estimates with greater than or less than figures
relative to established cost-effectiveness thresholds. These were pre-
sented in the table, but the boundary value was used to calculate the
statistical mean and median cost-effectiveness values for the sampled
drugs.
Eleven cancer drugs were ultimately included in our study (Fig. 1).
Each was a biologic or immunotherapy, indicated for treatment of
recurrent, relapsed, advanced or metastatic tumor. Three drugs were
indicated for treatment of non-small cell lung cancer and ovarian
cancer, two were CAR-T therapies (one for acute leukemia and the
other for lymphoma), and two were for multiple myeloma and one
for prostate cancer (eTable 1 and eTable 2).
2.2. Statistical analysis
The primary outcome for selection was cost-effectiveness mea-
sured using the incremental cost-effectiveness ratio. This was avail-
able in US dollars for ICER and Great British pounds per QALY for
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cost-effectiveness of health interventions measuring the difference in
cost divided by the difference in clinical effect.
Assessment reports were analyzed and data was extracted for the
following characteristics: cost-effectiveness using the incremental
cost-effectiveness ratio, clinical benefit measured in QALYs gained,
date of assessment, comparator treatment used in determining cost-
effectiveness, price the calculation was based upon (often list price or
wholesale acquisition cost), final recommendation and the criteria
and design of the economic evaluation. Other variables collected
from the assessment reports for the methodology and criteria
included; the perspective of the economic evaluation, type of model,
time horizon, cycle length, discount rate, outcomes, clinical trials and
the assumptions used in the estimate (eTable 1).
A detailed analysis of the modeling of clinical efficacy and health
equities used to determine incremental QALYs gained by a drug was
not completed in our assessment because the majority of clinical
data from NICE appraisals was redacted. Therefore, it was not possi-
ble to compare how ICER and NICE evaluated the clinical benefit of
cancer drugs included in our study. The incremental cost-effective-
ness ratio calculated by NICE was converted to US dollars using US
gross domestic product purchasing power parity from the year the
final recommendation was made or the nearest year with available
data [9].




We found that eleven cancer drugs were commonly assessed by
ICER and NICE from 2016 to 2019 and evaluated for cost-effective-
ness using the measure of incremental cost per QALY (Table 1)[10].
ICER uses a cost-effectiveness threshold of $100,000 to $150,000 per
QALY or below. In comparison, NICE utilizes a much lower threshold
of £20,000 to £30,000 per QALY ($28,471 - 42,857) [11].
Methodologically, both ICER and NICE utilize similar comparators
and approaches for estimating cost-effectiveness. They use compara-
ble economic tools and assumptions: lifetime time horizon for mea-
suring effect, economic modeling using partitioned and Markov
models, an economic perspective from the payer’s point of view, dis-
count rates of approximately 3%, length of treatment cycle matched
to the drug, and key outcomes measured including cost, life years
gained, QALYs, and the incremental cost-effectiveness ratio. How-
ever, some appraisals had discordant comparators for evaluating
cost-effectiveness, such as tisagenlecleucel (ICER used clofarabine as
a comparator and NICE used blinatumomab or salvage chemother-
apy) (Table 1). Both ICER and NICE encounter similar limitations with
modeling clinical effectiveness. Many surrogate measures used for
cancer therapies are not strongly correlated with clinically meaning-
ful outcomes, such as overall survival [12]. Consequently, calculating
QALYs gained using surrogate measures or immature clinical data
lead to less than definitive results by relying on uncertain assump-
tions and extrapolation of multiple variables. This is because the final
estimate for cost-effectiveness requires statistical modeling, which
may be based upon information from surrogate measures, immature
data for clinical outcomes, or small or unrepresentative patient
cohorts.
3.2. Cost-effectiveness: the Institute for Clinical and Economic Review
We find that four drugs were deemed cost-effective by ICER and
valued below the $150,000 per QALY threshold, recommended forformulary inclusion at the stated list price (Table 1). For the
remaining seven drugs, ICER does not recommend including them
at the stated list price without further rebates or discounts. For
drugs which are not cost-effective, ICER performs a budget
impact analysis based on the available list or net price to calcu-
late discount rates that would make the drug fall below their
cost-effective threshold. The rationale is that individual payers
will use ICER reports as evidence in negotiations with manufac-
turers to achieve lower prices.
The mean and median incremental cost per QALY appraised by
ICER was $233,302 and $236,492, respectively. Panobinostat had the
lowest cost per QALY valuation at $10,230 while ixazomib had the
highest, $433,794. On average, a price discount of 51% is required to
improve the cost-effectiveness of these seven drugs to $150,000 per
QALY and a discount of 68% is needed to achieve a cost-effectiveness
of $100,000 per QALY.
3.3. Cost-effectiveness: England’s National IInstitute for Health and Care
Excellence
NICE rarely identifies a single cost per QALY value for cost-effec-
tiveness. Instead, it deliberates with the manufacturer to propose a
range of possible cost-effectiveness values and then broadly decides
whether the drug’s value likely falls above or below the established
threshold. Two drugs were within the cost-effectiveness threshold
accepted by NICE at less than $28,471 - $42,857 per QALY, however,
with a degree of uncertainty (panobinostat and ixazomib). The
majority of cancer drugs (7/11) were valued above $42,857 but less
than $71,429 (£50,000), a second higher threshold for end-of-life
care and rare conditions that applies to most of these cancer thera-
pies [11]. Only one drug, enzalutamide, was not recommended for
use in England as it was definitively above the end-of-life threshold
at $80,240 and had questionable certainty for overall survival. In con-
trast, axicabtagene ciloleucel was not cost-effective but recom-
mended for coverage via the NHS subject to a financial agreement
(since the manufacturer was able to reach a price agreement where
the drug was cost-effective) and additional data for efficacy.
In total, ten drugs were recommended by NICE for coverage via
the NHS and all ten drugs included a financial agreement to improve
cost-effectiveness. Further, seven of the ten recommended drugs
were subject to additional evidence for efficacy and recommended
for use via England’s Cancer Drugs Fund (CDF). The CDF provides
access to cancer drugs that have significant uncertainty for clinical
and cost-effectiveness but have potential for routine use. Through
the CDF, real world evidence for clinical effectiveness is collected to
reduce uncertainty and inform clinical decision making in the NHS
[13].
3.4. Discordance
Despite large discrepancies in their cost per QALY valuations, ICER
and NICE agreed with the majority (7/11) of recommendations to
payers. Cancer drugs with positive recommendations tended to be
more reasonably priced in the US or received discounts with financial
agreements in England. Alternatively, drugs with negative recom-
mendations often had high prices, were cost-ineffective, or had a sig-
nificant budget impact. ICER and NICE were in discordance for 4/11
drugs. For three drugs, discordance was due to the higher cost-effec-
tiveness threshold set by ICER, and higher US drug prices. For the
remaining drug (enzalutamide), clinical effectiveness data from a sur-
rogate endpoint resulted in opposing recommendations. ICER’s
appraisal for enzalutamide was based upon evidence from metasta-
sis-free survival (a surrogate endpoint) and immature overall survival
data to validate clinical benefit. In contrast, NICE did not believe enza-
lutamide was clinically effective as the data for overall survival was
both immature and not significant.
Table 1
Cost-effectiveness evaluations and coverage recommendations from ICER and NICE.
Indication Drug Incremental cost-effectiveness ratio Recommendation Concordance of
Recommendations
Reason for Discordance





$219,179 < $71,429 High certainty for benefit despite uncer-
tain evidence, exceeds cost-effective-
ness (factor of uncertainty)
Recommended with financial agreement Yes N/A; not cost-effective in
either US or England
Nivolumab (Opdivo) $415,950 $72,379 High certainty for benefit despite uncer-
tain evidence, exceeds cost-effective-
ness (factor of uncertainty)
Recommended with a financial and post-
market efficacy agreement
Yes N/A; not cost-effective in
either US or England
Pembrolizumab
(Keytruda)
$236,492 < $71,429 High certainty for benefit despite uncer-
tain evidence, exceeds cost-effective-
ness (factor of uncertainty)
Recommended with financial agreement Yes N/A; not cost-effective in




Rucaparib (Rubraca) $369,175 > $42,857 Quality adjusted and OS benefit but not
priced in alignment with benefit
Recommended with a financial and post-
market efficacy agreement
Yes N/A; not cost-effective in
either US or England
Niraparib (Zejula) $291,454 $53,804 Quality adjusted and OS benefit, but the
price is not aligned with the benefit
Recommended with a financial and post-
market efficacy agreement
Yes N/A; not cost-effective in
either US or England
Olaparib (Lynparza) $324,100 > $42,857 Quality adjusted and OS benefit but not
priced in alignment with benefit for
platinum sensitive disease
Recommended with a financial and post-
market efficacy agreement
Yes N/A; not cost-effective in
either US or England
Multiple Myeloma Panobinostat (Farydak) $10,230 < $35,765 Promising but concerns over toxicity,
long-term cost-effectiveness is
uncertain
Recommended with financial agreement Yes N/A; cost-effective in both US
and England
Ixazomib (Ninlaro) $433,794 < $42,857 Moderate certainty for health benefit, not
representative of long-term value at
list price
Recommended with a financial and post-
market efficacy agreement





$45,871 > $42,857  $64,286 Net health benefit, potentially cost-effec-
tive but more evidence for PFS and OS
is needed to reduce uncertainty of clin-
ical and cost-effectiveness
Recommended with a financial and post-
market efficacy agreement
No Higher cost-effectiveness
threshold in the US
Lymphoma Axicabtagene ciloleucel
(Yescarta)
$136,078 > $71,429 Net health benefit, cost-effective Recommended with a financial and post-
market efficacy agreement
No Higher cost-effectiveness
threshold in the US
Prostate Cancer Enzalutamide (Xtandi) $84,000 $80,240 High certainty of substantial net health
benefit (based on MFS and immature
OS data), cost-effective
Not recommended; immature OS evidence
not significant, not cost-effective with
financial agreement
No Higher cost-effectiveness
threshold in the US, discor-
dance regarding clinical
effectiveness
Abbreviations: ICER; Institute for Clinical and Economic Review, NICE; the National Institute for Health and Care Excellence, PFS; progression-free survival, MFS; metastasis-free survival, OS; overall survival.
Notes: Drug evaluations from ICER and NICE differ because of their function within the two healthcare systems. In the United Kingdom, NICE makes recommendations for funding decisions in the NHS whereas in the United States, ICER
does not have a funding mandate and does not make formal decisions for reimbursement. Therefore, the recommendations from the two agencies are distinct and presented differently.
1. For NICE’s assessment of atezolizumab the ICER was confidential due to the patient access scheme. NICE explained the ICER was similar to pembrolizumab and likely cost-effective. Less than $71,429 per QALY was used as an educated
assumption based on the information given.
2. For the assessment of rucaparib, ICER used comparators of Pegylated liposomal doxorubicin + carboplatin while NICE used comparators of routine surveillance or olaparib.
3. For NICE’s assessment of olaparib the base-case ICER was $42,857 per QALY but this was stated to over value treatment. NICE stated treatment was not a cost-effective use of resources compared with routine surveillance therefore an
educated assumption (greater than £30 K per QALY) was used.
4. ICER compared a combination therapy of panobinostat with bortezomib and dexamethasone versus bortezomib and dexamethasone. NICE compared panobinostat with bortezomib and dexamethasone versus lenalidomide and dexa-
methasone. ICER also made this comparison but found that lenalidomide and dexamethasone was cheaper and more cost-effective than the therapy with panobinostat.
5. Ixazomib is indicated with lenalidomide and dexamethasone.
6. For tisagenlecleucel, NICE and ICER used different comparators. ICER compared tisagenlecleucel to clofarabine while NICE compared it with a composite of salvage chemotherapy as well as blinatumomab. NICE determined that tisagen-
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ICER and NICE evaluate cancer drugs to support cost-effective
healthcare decisions and value-based pricing (according to the value
of the drug rather than market dynamics, cost, or historical prices).
As they use similar data and methods for determining cost-effective-
ness, they come out with remarkably similar results. But there are
important ways in which they diverge, largely due to contextual dif-
ferences between the US and English health systems and because
ICER and NICE have different remits.
Our analysis shows that NICE’s capacity to negotiate price dis-
counts and access schemes result in much lower cost per QALY valua-
tions and more favourable recommendations than those of ICER for
similarly assessed cancer drugs  largely due to its sanctioned role in
healthcare decisions for England in contrast to ICER’s voluntary non-
profit role which has no enforcement over pricing or coverage deci-
sions in the US. Differences in NICE’s role within healthcare decisions
for coverage and funding are part of the reason why it helps achieve
lower drug prices in England. Almost all cancer drugs assessed by
ICER were cost-ineffective at the list or net price and required sub-
stantial discounts to reach their cost-effectiveness threshold (a
threshold that is much higher than the one used by NICE). ICER’s
higher cost-effectiveness valuations and chosen cost-effectiveness
thresholds likely reflect the higher US drug prices and cost of health-
care inputted into their economic models. In 2018, US gross domestic
product per capita spent on healthcare ($10,586) was almost three
times greater than the UK ($4070) [14]. While challenges with esti-
mating clinical effectiveness in new cancer drugs, such as relying on
poorly validated surrogate measures, may contribute to cost-effec-
tiveness variation, it does not appear to be a major factor in the con-
sistently higher cost-effectiveness ratios presented by ICER.
With growing adoption of ICER assessments, US private insurers
now have a standard for measuring the comparative value gained
from new cancer treatments. This will continue to send price signals
to the US market that high cost cancer drugs with marginal or uncer-
tain benefit are likely to receive unfavorable coverage recommenda-
tions. Private insurers are then in a better, more informed position to
negotiate price discounts off the list price. In contrast to private
insurers which have some discretion in limiting formulary inclusion,
Medicare and Medicaid, two of the largest payers in the US, are
required to include nearly every FDA-approved cancer drug within
the public formulary [15]. Consequently, public financing for cancer
drugs in the US particularly suffers from inefficiencies, whereby
Medicare and Medicaid are required to pay for me-too cancer drugs
and drugs without validated improvements in clinical or cost-effec-
tiveness over the standard of care [16]. Since public payors such as
Medicare are required to cover most new cancer drugs regardless of
price, private insurers have less flexibility to negotiate price dis-
counts because Medicare is willing to cover the full cost of the drug.
Due to the unique structure of the US health system and its socio-
political context, the US market is unlikely to accept a lower cost-
effectiveness threshold or integrate a public HTA agency. In fact,
there may be consequences to the pharmaceutical market if the US,
the largest payer of new innovative pharmaceutical products, sub-
stantially lowers drug prices. However, NICE provides a stark
reminder of how much lower other countries pay for cancer drugs
and other pharmaceuticals. NICE employs several policy tools, such
as value-based pricing, direct price negotiations and patient access
schemes (which lower the acquisition cost of the drug to improve
cost-effectiveness or limit prescribing to patient subgroups), that
could be modified for the US market to help insurers, particularly
Medicare and Medicaid, achieve better value.
This study has limitations. From the eleven drugs assessed by
NICE, all eleven included a financial agreement used to improve the
cost-effectiveness of drugs under review for coverage from the
English National Health Service (NHS). This requires a negotiatedagreement between the manufacturer and the regulator for public
healthcare in England (NHS England), to submit the drug to the NHS
at a discounted, confidential price. As such, the list price without the
patient access scheme was available in public assessment reports
produced by NICE [17]. The discounted price was used by NICE in the
assessment of cost-effectiveness; however, this price remains confi-
dential under the agreement. Therefore, the cost-effectiveness results
reflect the list price after accounting for rebates and discounts from
the manufacturer.
As noted above, NICE makes recommendations based on a range
of possible cost-effectiveness values. The evidence review committee
will broadly decide whether the balance of evidence suggests that
the drug can be considered cost-effective relative to established cost-
effectiveness thresholds (£20,000 to £30,000 per QALY). Conse-
quently, a single cost per QALY often cannot be used to compare with
that determined by ICER. In these cases, we provided the ‘greater
than’ or ‘less than’ value identified by NICE. When calculating the
mean and median cost per QALY we use the threshold value that
NICE provides, which will trend these values toward the threshold
itself. However, due to the nature of discount negotiations the range
of cost per QALYs is not far from the threshold value. In contrast, ICER
uses variable prices in their assessment of cost-effectiveness. These
included the Medicare price, the wholesale acquisition cost (list
price) or the net price depending on the drug. The list price did not
reflect future discounts, voucher schemes, and rebates. Payers will
then conduct their own private negotiations, similar to NICE, to
achieve more cost-effective prices. Therefore, this study will over-
state the true difference in cost-effectiveness of these cancer drugs
listed in the US and England. However, even if payers were able to
achieve the theoretical discount levels recommended by ICER, the
cost-effectiveness will still be higher than that obtained by NICE
because ICER utilizes a higher cost-effectiveness threshold. Lastly,
cost-ineffective was used to describe both drugs with known clinical
efficacy per unit of cost (e.g. pembrolizumab), and drugs with uncer-
tain efficacy and more reasonable cost (e.g. panobinostat).
Spending on costly new cancer therapeutics is increasing for
payers and health systems in the US and England. Among 11 new
cancer drugs commonly evaluated by ICER and NICE, both drug
assessment agencies used similar HTA methods and were in concor-
dance for the majority of their cost-effectiveness recommendations.
They concluded that most new cancer drugs represent low value for
money at current prices. Both higher US prices and a higher cost-
effectiveness threshold used by ICER were the primary reasons for
divergence in the remaining assessments. A growing number of pri-
vate US insurers look to ICER for cost-effectiveness valuations which
will help send price signals to manufacturers that expensive cancer
drugs with marginal or uncertain benefit are less likely to be covered
by these insurers. While differences in health system and sociopoliti-
cal context may prevent US acceptance of a lower cost-effectiveness
threshold or public integration of an HTA body, NICE provides an
important perspective for how much lower other countries pay for
pharmaceuticals and provides examples of policy tools that may help
US health insurers, particularly Medicare and Medicaid, achieve bet-
ter value.Data sharing
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